跳至主要内容
临床试验/NCT02773147
NCT02773147Unknown2 期

Effect of Vitamin B Substitution on Plasma NFL and Neurocognitive Performance in HIV-infected Individuals With Increased Plasma Homocysteine

Göteborg University1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2016年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
发起方
入组人数
60
试验地点
1
主要终点
Declining NFL or decreased rate of increase of NFL

研究概览

简要总结

The purpose of this study is to investigate if B vitamin substitution have effect on NFL (neurofilament light protein) plasma levels and neurocognitive performance in HIV-infected individuals with increased plasma homocysteine

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The ability to understand and give informed consent to participate.
  • HIV-1 infected with stable ART > 12 months
  • Plasma HIV-RNA < 50 copies/ml
  • Plasma homocysteine ≥ 12 μmol/L (subjects with < 12 μmol/L will be included in the analysis of secondary endpoint 3 (see 5.4).
  • Male or female, age 18 or older.

排除标准

  • Treatment with trimethoprim-sulfamethoxazole or methotrexate
  • Ongoing B6, B12 or folate substitution
  • Antiepileptic treatment
  • Small bowel or ventricular resection
  • Disturbed absorption in small bowel (Mb Crohn, untreated coeliac disease)
  • Ongoing neurological disease or severe psychiatric disease
  • Any malignant tumor in the history.
  • Severe ongoing infection or opportunistic infection
  • AUDIT > 7 for men and > 5 for women
  • MADRS > 20
  • Significant B12 or folate deficiency that indicate substitution (all subjects will be offered adequate substitution, they will be included in the analysis of secondary endpoint 3 (see 5.4)).
  • Pregnancy at screening visit, or planning pregnancy during study period is an exclusion criteria. (Not due to toxicity of Triobe, but to elevated risk of being prescribed B-vitamins outside of trial. If study object gets pregnant during study, she can continue the study but must be excluded if she starts treatment with other B-vitamin treatment than Triobe.)

研究组 & 干预措施

Triobe

Experimental

Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.

干预措施: Cyanocobalamin (Drug)

Triobe

Experimental

Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.

干预措施: Folate (Drug)

Triobe

Experimental

Cyanocobalamin 0,5 mg. Daily for 24 months. Folate 0,8 mg. Daily for 24 months. Pyridoxine 3,0 mg. Daily for 24 months.

干预措施: Pyridoxine (Drug)

结局指标

主要结局

Declining NFL or decreased rate of increase of NFL

时间窗: One year

次要结局

未报告次要终点

研究者

发起方
Göteborg University
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验